litlas
ログインアカウント作成

Ralf Gutzmer

2002–2025 年に発表

194
論文数
35,725
被引用数
83
h 指数
182
i10 指数

被引用数

Ralf Gutzmer の年別被引用数1991 年: 被引用 1 件1997 年: 被引用 3 件2002 年: 被引用 1 件2003 年: 被引用 7 件2004 年: 被引用 4 件2005 年: 被引用 6 件2006 年: 被引用 14 件2007 年: 被引用 11 件2008 年: 被引用 23 件2009 年: 被引用 51 件2010 年: 被引用 28 件2011 年: 被引用 39 件2012 年: 被引用 50 件2013 年: 被引用 123 件2014 年: 被引用 202 件2015 年: 被引用 264 件2016 年: 被引用 431 件2017 年: 被引用 564 件2018 年: 被引用 581 件2019 年: 被引用 1,730 件2020 年: 被引用 2,048 件2021 年: 被引用 2,048 件2022 年: 被引用 1,742 件2023 年: 被引用 1,285 件2024 年: 被引用 2,032 件2025 年: 被引用 796 件2026 年: 被引用 16 件1992〜1996 年は被引用が無いため表示していません1998〜2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,080 件、この内訳の 23.9%中国: 引用元論文 2,010 件、この内訳の 11.8%ドイツ: 引用元論文 1,218 件、この内訳の 7.2%イタリア: 引用元論文 1,073 件、この内訳の 6.3%イギリス: 引用元論文 894 件、この内訳の 5.3%フランス: 引用元論文 824 件、この内訳の 4.8%オーストラリア: 引用元論文 739 件、この内訳の 4.3%オランダ: 引用元論文 533 件、この内訳の 3.1%スペイン: 引用元論文 522 件、この内訳の 3.1%スイス: 引用元論文 502 件、この内訳の 3%日本: 引用元論文 448 件、この内訳の 2.6%カナダ: 引用元論文 426 件、この内訳の 2.5%
0%23.9%その他 22.1%

機関

分野

  • Medicine63.5%
  • Biochemistry, Genetics and Molecular Biology24.6%
  • Immunology and Microbiology8.3%
  • Engineering0.8%
  • Computer Science0.6%
  • Neuroscience0.5%
  • その他1.7%

トピック

  • Cancer Immunotherapy and Biomarkers15.7%
  • Melanoma and MAPK Pathways6.8%
  • Immunotherapy and Immune Responses6.5%
  • CAR-T cell therapy research5.3%
  • Cutaneous Melanoma Detection and Management5.3%
  • Immune Cell Function and Interaction2.3%
  • その他58.1%

共著者

全論文

検索で開く
  1. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

    著者: Eliezer M. Van Allen, Diana Miao, Bastian Schilling, Sachet A. Shukla, Christian U. Blank, Lisa Zimmer, Antje Sucker, Uwe Hillen, Marnix H. Geukes Foppen, Simone M. Goldinger, Jochen Utikal, Jessica C. Hassel, Benjamin Weide, Katharina C. Kaehler, Carmen Loquai, Peter Mohr, Ralf Gutzmer, Reinhard Dummer, Stacey Gabriel, Catherine J. Wu, Dirk Schadendorf, Levi A. Garraway - Science 2015 被引用: 2,995

  2. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

    著者: David Liu, Bastian Schilling, Derek Liu, Antje Sucker, Elisabeth Livingstone, Livnat Jerby‐Arnon, Lisa Zimmer, Ralf Gutzmer, Imke Satzger, Carmen Loquai, Stephan Grabbe, Natalie I. Vokes, Claire A. Margolis, Jake R. Conway, Meng Xiao He, Haitham Elmarakeby, Felix Dietlein, Diana Miao, Adam Tracy, Helen Gogas, Simone M. Goldinger, Jochen Utikal, Christian U. Blank, Ricarda Rauschenberg, Dagmar von Bubnoff, Angela M. Krackhardt, Benjamin Weide, Sebastian Haferkamp, Felix Kiecker, Ben Izar, Levi A. Garraway, Aviv Regev, Keith T. Flaherty, Annette Paschen, Eliezer M. Van Allen, Dirk Schadendorf - Nature Medicine 2019 被引用: 1,105

  3. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    著者: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert - New England Journal of Medicine 2018 被引用: 1,853

  4. Melanoma

    著者: Dirk Schadendorf, Alexander C. J. van Akkooi, Carola Berking, Klaus Griewank, Ralf Gutzmer, Axel Hauschild, Andreas Stang, Alexander Roesch, Selma Ugurel - The Lancet 2018 被引用: 1,468

  5. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

    著者: Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin - The Lancet Oncology 2015 被引用: 2,666

  6. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Светлана Проценко, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy M. Manikhas, Yibing Yan, Kuan-Chieh Huang, Anne Uyei, Virginia McNally, Grant A. McArthur, Paolo A. Ascierto - The Lancet 2020 被引用: 650

  7. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

    著者: Jason Chesney, Antoni Ribas, Georgina V. Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Höeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes V. van Thienen, Sebastian Haferkamp, Josep Malvehy, Bernardo L. Rapoport, Ari M. Vanderwalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, F. Stephen Hodi, Helen Gogas - Journal of Clinical Oncology 2022 被引用: 284

  8. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

    著者: Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty - The Lancet Oncology 2018 被引用: 1,016

  9. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    著者: Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U. Blank, Wilson H. Miller, Eckhart Kaempgen, Salvador Martín‐Algarra, Bogusława Karaszewska, Cornelia Mauch, Vanna Chiarion‐Sileni, Anne-Marie Martin, S. Swann, Patricia Haney, Beloo Mirakhur, Mary Guckert, Vicki Goodman, Paul B. Chapman - The Lancet 2012 被引用: 2,960

  10. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

    著者: Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci ほか 32 名 - The Lancet Oncology 2021 被引用: 389

  11. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

    著者: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Caroline Robert, Stefan Suciu - JAMA Oncology 2020 被引用: 436

  12. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients WithBRAFV600–Mutant Melanoma

    著者: Reinhard Dummer, Keith T. Flaherty, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo A. Ascierto - Journal of Clinical Oncology 2022 被引用: 185

  13. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

    著者: Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Marye J. Boers‐Sonderen, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C. J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Clemens Krepler, Sandrine Marréaud, Stefan Suciu, Caroline Robert - NEJM Evidence 2022 被引用: 150

  14. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

    著者: Reinhard Dummer, Paolo A. Ascierto, Helen Gogas, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion‐Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty - The Lancet Oncology 2018 被引用: 586

  15. International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

    著者: Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, Helmut L. Haas - Pharmacological Reviews 2015 被引用: 560

  16. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

    著者: James Larkin, David R. Minor, Sandra P. D’Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald P. Linette, Bartosz Chmielowski, Christopher D. Lao, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Mario Sznol, Adil Daud, Jeffrey A. Sosman, Nikhil I. Khushalani, Dirk Schadendorf, Christoph Höeller, Dana Walker, George Kong, Christine E. Horak, Jeffrey S. Weber - Journal of Clinical Oncology 2017 被引用: 510

  17. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

    著者: Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, Ana Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandalà, L. Thomas, Lev Demidov, Claus Garbe, David Hogg, Gabriella Liszkay, Paola Queirolo, Ernesto Wasserman, James Ford, Marine Weill, L. Andres Sirulnik, Valentine Jehl, Viviana Bozón, Georgina V. Long, Keith T. Flaherty - The Lancet Oncology 2017 被引用: 491

  18. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

    著者: Alexander Stratigos, Aleksandar Sekulić, Ketty Peris, Oliver Bechter, S. Prey, Martin Kaatz, Karl D. Lewis, Nicole Basset‐Séguin, Anne Lynn S. Chang, Stéphane Dalle, Almudena Fernández Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R. Migden, Reinhard Dummer, Siyu Li, Suk-Young Yoo, Kosalai Kal Mohan, Ebony Coates, Vladimir Janković, Nathalie Fiaschi, Emmanuel Chiebuka Okoye, Ioannis D. Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Gavin Thurston, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Timothy G. Bowler, Matthew G. Fury - The Lancet Oncology 2021 被引用: 278

  19. The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

    著者: Eliezer M. Van Allen, Nikhil Wagle, Antje Sucker, Daniel J. Treacy, Cory M. Johannessen, Eva M. Goetz, Chelsea S. Place, Amaro Taylor‐Weiner, Steven R. Whittaker, Gregory V. Kryukov, Eran Hodis, Mara Rosenberg, Aaron McKenna, Kristian Cibulskis, Deborah Farlow, Lisa Zimmer, Uwe Hillen, Ralf Gutzmer, Simone M. Goldinger, Selma Ugurel, Helen Gogas, Friederike Egberts, Carola Berking, Uwe Trefzer, Carmen Loquai, Benjamin Weide, Jessica C. Hassel, Stacey Gabriel, Scott L. Carter, Gad Getz, Levi A. Garraway, Dirk Schadendorf - Cancer Discovery 2013 被引用: 940

  20. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

    著者: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus Johannes Maria van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert - Journal of Clinical Oncology 2020 被引用: 281

  21. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

    著者: Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stéphane Dalle, Nicolás Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Muñoz‐Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean‐Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz‐Merino, André van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Öcek Baş, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina V. Long - Journal of Clinical Oncology 2022 被引用: 162

  22. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

    著者: Benjamin Weide, Alexander Martens, Jessica C. Hassel, Carola Berking, Michael A. Postow, Kees Bisschop, Ester Simeone, Johanna Mangana, Bastian Schilling, Anna Maria Di Giacomo, Nicole Brenner, Katharina C. Kähler, Lucie Heinzerling, Ralf Gutzmer, Armin Bender, Christoffer Gebhardt, Emanuela Romano, Friedegund Meier, Peter Martus, Michele Maio, Christian U. Blank, Dirk Schadendorf, Reinhard Dummer, Paolo A. Ascierto, Geke A.P. Hospers, Claus Garbe, Jedd D. Wolchok - Clinical Cancer Research 2016 被引用: 584

  23. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

    著者: Lars Hofmann, Andrea Forschner, Carmen Loquai, Simone M. Goldinger, Lisa Zimmer, Selma Ugurel, Maria Isabel Schmidgen, Ralf Gutzmer, Jochen Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Ioannis Thomas, Carsten Weishaupt, Martin Leverkus, R.U. Wahl, Ursula M. Dietrich, Claus Garbe, Michael Constantin Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie Heinzerling - European Journal of Cancer 2016 被引用: 647

  24. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

    著者: Paolo A. Ascierto, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl D. Lewis, Светлана Проценко, Rodrigo Perez Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Natalia V. Zhukova, Jacob Schachter, Yibing Yan, Ivor Caro, Christian Hertig, Cloris Xue, Lieke Kusters, Grant A. McArthur, Ralf Gutzmer - The Lancet Oncology 2022 被引用: 104